Stabile Zieleditierende Guide-Rna mit Darin Eingeführter Phosphatteilmodifikation

EP4768581 6. März 2025

Anmelder: Fukuoka University, Daiichi Sankyo Company, Limited 🇯🇵

Details

Veröffentlichungs-Nr.
EP4768581
Anmeldetag
26. August 2024
Veröffentlichung
6. März 2025
Rechtsraum
EP
IPC
C12N15/11, C12N15/09
Offizieller Volltext

Abstract

Provided is an oligonucleotide capable of inducing the editing activity of ADAR in a cell and having excellent stability. The oligonucleotide includes a first oligonucleotide and a second oligonucleotide linked to the 5' side of the first oligonucleotide, and is capable of inducing the site-specific editing in the target RNA. The first oligonucleotide is composed of a target-corresponding nucleoside residue corresponding to an adenosine residue in the target RNA, an oligonucleotide containing 3 to 6 residues, linked to the 5' side of the target-corresponding nucleoside residue, and having a base sequence complementary to the target RNA and an oligonucleotide containing 10 to 24 residues, linked to the 3' side of the target-corresponding nucleoside residue, and having a base sequence complementary to the target RNA, and at least one phosphorus-containing linking group selected from the group consisting of a phosphorus-containing linking group linking a 1st nucleoside residue and a 2nd nucleoside residue and a phosphorus-containing linking group linking a 4th nucleoside residue and a 5th nucleoside residue, counting in the 3' direction from the target-corresponding nucleoside residue, is at least one selected from the group consisting of an alkylphosphonic residue, an alkyl phosphate residue, and a substituted phosphoramide residue. At the 3' end of the second oligonucleotide, a nucleoside residue corresponding to a nucleoside residue of the target RNA is deleted, or, at the 3' end, the second oligonucleotide has a nucleoside residue that does not form a complementary pair with the nucleoside residue of the target RNA, and contains 2 to 10 residues, and nucleoside residues at least other than at the 3' end are complementary to the target RNA.

Anmelder

Firmen
Fukuoka University
Daiichi Sankyo Company, Limited
Land
🇯🇵 Japan
🇯🇵 Daiichi Sankyo Company, Limited

Daiichi Sankyo ist ein japanischer Pharmakonzern und hält zahlreiche Patente im Bereich Arzneimittel, insbesondere zu Onkologie sowie kardiovaskulären und Infektionskrankheiten.

853 Patente in unserer Datenbank

Noch Fragen?

Wir helfen Ihnen gerne weiter. Schreiben Sie uns einfach.

Kontakt aufnehmen